Pages that link to "Q37604524"
Jump to navigation
Jump to search
The following pages link to A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy (Q37604524):
Displaying 50 items.
- Epigenetic control of HIV-1 post integration latency: implications for therapy (Q26781191) (← links)
- HIV-1 functional cure: will the dream come true? (Q26865803) (← links)
- Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents (Q28079455) (← links)
- An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1 JQ1 and Ingenol-B JQ1 to Potently Reactivate Viral Gene Expression (Q28546918) (← links)
- Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV (Q28551642) (← links)
- Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1 (Q28655602) (← links)
- Measuring reversal of HIV-1 latency ex vivo using cells from infected individuals (Q33627182) (← links)
- Benzotriazoles Reactivate Latent HIV-1 through Inactivation of STAT5 SUMOylation. (Q33771155) (← links)
- Immunologic strategies for HIV-1 remission and eradication (Q33896523) (← links)
- Progress towards an HIV cure: update from the 2014 International AIDS Society Symposium (Q34869380) (← links)
- A primary CD4( ) T cell model of HIV-1 latency established after activation through the T cell receptor and subsequent return to quiescence (Q35229849) (← links)
- Eradicating HIV-1 infection: seeking to clear a persistent pathogen (Q35252186) (← links)
- Compartmentalization, Viral Evolution, and Viral Latency of HIV in the CNS. (Q35606068) (← links)
- HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days--Implications for HIV Remission (Q35680431) (← links)
- Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. (Q35720063) (← links)
- Effect of ipilimumab on the HIV reservoir in an HIV-infected individual with metastatic melanoma (Q35822484) (← links)
- Human Galectin-9 Is a Potent Mediator of HIV Transcription and Reactivation (Q36037844) (← links)
- Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4( ) T Cells from Aviremic Patients (Q36076018) (← links)
- CRISPR/gRNA-directed synergistic activation mediator (SAM) induces specific, persistent and robust reactivation of the HIV-1 latent reservoirs (Q36250079) (← links)
- HIV-1 latency and virus production from unintegrated genomes following direct infection of resting CD4 T cells (Q36428308) (← links)
- CNS-specific regulatory elements in brain-derived HIV-1 strains affect responses to latency-reversing agents with implications for cure strategies (Q36719187) (← links)
- Advances and hope for perinatal HIV remission and cure in children and adolescents (Q36737063) (← links)
- The BET inhibitor OTX015 reactivates latent HIV-1 through P-TEFb (Q36790027) (← links)
- Animal models to achieve an HIV cure (Q37041160) (← links)
- Broad activation of latent HIV-1 in vivo (Q37260309) (← links)
- Activation of HIV-1 expression in latently infected CD4 T cells by the small molecule PKC412. (Q37356604) (← links)
- Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study (Q37413059) (← links)
- Janus kinase inhibition suppresses PKC-induced cytokine release without affecting HIV-1 latency reversal ex vivo (Q37522861) (← links)
- New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. (Q37695001) (← links)
- Targeting HIV latency: resting memory T cells, hematopoietic progenitor cells and future directions (Q38246141) (← links)
- HIV eradication: combinatorial approaches to activate latent viruses (Q38271132) (← links)
- Application of gene-editing technologies to HIV-1. (Q38328699) (← links)
- Multiple Origins of Virus Persistence during Natural Control of HIV Infection (Q38379102) (← links)
- Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1. (Q38415577) (← links)
- Progress and challenges in the use of latent HIV-1 reactivating agents (Q38509230) (← links)
- Landscape review of current HIV 'kick and kill' cure research - some kicking, not enough killing. (Q38636019) (← links)
- HIV-1 Eradication: Early Trials (and Tribulations). (Q38675631) (← links)
- Perspectives on Human Immunodeficiency Virus (HIV) Cure: HIV Persistence in Tissue (Q38682294) (← links)
- Standard vaccines increase HIV-1 transcription during antiretroviral therapy. (Q38840779) (← links)
- Novel immunological strategies for HIV-1 eradication (Q38915896) (← links)
- Toward development of epigenetic drugs for central nervous system disorders: Modulating neuroplasticity via H3K4 methylation. (Q38916715) (← links)
- Toxicity and in vitro activity of HIV-1 latency-reversing agents in primary CNS cells (Q38924992) (← links)
- Current views on HIV-1 latency, persistence, and cure. (Q38973362) (← links)
- The Alphabet Soup of HIV Reservoir Markers (Q39237000) (← links)
- A Critical Review of the Evidence Concerning the HIV Latency Reversing Effect of Disulfiram, the Possible Explanations for Its Inability to Reduce the Size of the Latent Reservoir In Vivo, and the Caveats Associated with Its Use in Practice (Q39279515) (← links)
- Identification of benzazole compounds that induce HIV-1 transcription. (Q40154908) (← links)
- No adverse safety or virological changes 2 years following vorinostat in HIV-infected individuals on antiretroviral therapy (Q40289284) (← links)
- Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents. (Q40331404) (← links)
- A Novel Toll-Like Receptor 9 Agonist, MGN1703, Enhances HIV-1 Transcription and NK Cell-Mediated Inhibition of HIV-1-Infected Autologous CD4 T Cells (Q40336664) (← links)
- Functional screening of guide RNAs targeting the regulatory and structural HIV-1 viral genome for a cure of AIDS. (Q40829178) (← links)